A team of investigators conducted a systematic review and meta-analysis to assess whether a shorter-than-recommended duration of antibiotic treatment can be effective for the management of acute uncomplicated cystitis.
The new guidance aims to support urologists and other clinicians in providing evidence-based care to their patients.
Findings showed that the trial failed to demonstrate noninferiority, with a responder rate of 67.8% for sulopenem at the test of cure visit compared with 73.9% for ertapenem (difference of -6.1%; [95% CI, -12.0, -0.1])
Several factors were associated with an increased risk of UTI recurrence. These included antibiotic exposure prior to treatment, pyelonephritis on diagnosis date, having a follow-up visit during antibiotic treatment, receiving parenteral antibiotics.
Fetroja® (cefiderocol) has been made available by Shionogi for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Protective association mainly seen in women, in never smokers, and for uncomplicated UTI.
Trimethoprim-sulfamethoxazole prophylaxis for vesicoureteral reflux in young children has no adverse effect on complete blood count, serum electrolytes, or creatinine, a study found.
The Food and Drug Administration (FDA) has approved Fetroja (cefiderocol; Shionogi) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The treatment is indicated for patients aged ≥18 years with limited or no alternative…
The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ATM-AVI (aztreonam and avibactam; Allergan) for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). Aztreonam is a monobactam that has activity against metallo β-lactamase…
A high dose and continuous infusion of cefoxitin has been associated with clinical success in treating febrile urinary tract infections in men caused by extended spectrum beta-lactamase–producing E coli.
